Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adam D. DeVore
Donor Type and Organ Preservation in Heart Transplantation: Association with Recovery Following Severe Primary Graft Dysfunction
Abbreviations CI (confidence interval) DCD (donation after circulatory death) DBD (donation after brain death) DPP (direct procurement and preservation) ECMO (extracorporeal membrane oxygenation) EVP (ex vivo heart perfusion) HR (hazard ratio) ICU (intensive care unit) IPTW (inverse probability of treatment weighting) IQR (interquartile range) LVEF (left ventricular ejection fraction) MCS (mechanical circulatory support) MICE (multiple imputation by chained equations) NRP (normothermic...
Between Withdrawal and Death: Can Machine Learning Improve DCD Utilization?
Abbreviations DCD (Donation after Circulatory Death) OPO (Organ Procurement Organization) ROC (Receiver Operating Characteristic) PR (Precision Recall) AUC (Area Under the Curve) Keywords machine learning Heart Transplantation heart transplantation following donation after brain death heart transplantation following donation after circulatory death Get full text access Log in, subscribe or purchase for full access. References 1. Lerman, J.B. ...
Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial
Keywords Heart failure Clinical trials Evidence before this study Heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, in part because medical therapy for HF is frequently underused and underdosed. Intensive optimization strategies can improve medication use. For example, structured, high-frequency in-person follow-up after hospitalization has been shown to increase HF medical therapy use and improve outcomes.
HFSA/AAHFN Tech in Heart Failure: How AI Can Help Heart Failure Care
A joint statement by the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN), published on January 27, 2026, emphasizes the value of integrating technology into all facets of heart failure care. The statement aims to provide clinicians with suggestions for a more team-based, forward-thinking, and actionable system of care.
HFSA/AAHFN Tech in Heart Failure: What Needs to Change in the Face of New Tech
A joint statement by the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN), published on January 27, 2026, emphasizes the value of integrating technology into all facets of heart failure care. The statement aims to provide clinicians with suggestions for a more team-based, forward-thinking, and actionable system of care.
HFSA/AAHFN Tech in Heart Failure: Interdisciplinary Integration in Heart Failure
A joint statement by the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN), published on January 27, 2026, emphasizes the value of integrating technology into all facets of heart failure care. The statement aims to provide clinicians with suggestions for a more team-based, forward-thinking, and actionable system of care.
HFSA/AAHFN Tech in Heart Failure: Bridging Trials and Clinical Practice
A joint statement by the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN), published on January 27, 2026, emphasizes the value of integrating technology into all facets of heart failure care. The statement aims to provide clinicians with suggestions for a more team-based, forward-thinking, and actionable system of care.
HFSA/AAHFN Tech in Heart Failure: Why Integration Matters
A joint statement by the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN), published on January 27, 2026, emphasizes the value of integrating technology into all facets of heart failure care. The statement aims to provide clinicians with suggestions for a more team-based, forward-thinking, and actionable system of care.
Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial
Get full access to this article View all available purchase options and get full access to this article. Supplemental Material File (circhf-2025-013231-s01.pdf) Supplemental Methods Tables S1–S6 References 1. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–366. doi: 10.1016/j.jacc.2018.04.070 2.
Failure to Launch: Insights From Randomized Trials on Implementation Strategies for Guideline-Directed Therapies for Heart Failure
References 1. "HF STATS 2024: heart failure epidemiology and outcomes statistics: an updated 2024 report from the Heart Failure Society of America". J Card Fail . 2025;31:1: 66-116. 2. "2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2022 3;79:17: e263-e421. 3.
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design
Heart failure with preserved ejection fraction and potential for mineralocorticoid receptor antagonists Heart failure (HF) with preserved ejection fraction (HFpEF) is a major and growing public health concern with limited treatment options.1-4 HFpEF is defined as HF with a left ventricular ejection fraction (LVEF) ≥50%.1 HF with a reduced ejection fraction has previously been defined as LVEF <40% and more recently ≤40%.
Increasing Utilization of Extended Criteria Donor Hearts for Transplantation: The OCS Heart EXPAND Trial
References 1. "Time is a precious commodity: 2018 OPTN policy change and the potential to lower heart transplant waitlist time in the sickest patients". Curr Cardiol Rep . 2019;21:7: 67. 2. "Does the heart transplant have a future?"Eur J Cardiothorac Surg . 2019;55:suppl 1: i38-i48. 3. "Epidemiology of heart failure". Circ Res . 2013;113:6: 646-659. 4. "The war against heart failure: the Lancet lecture". Lancet . 2015;385:9970: 812-824. 5. "Dilemmas in end-stage heart failure". J Geriatr Cardiol .
Increasing Utilization of Extended Criteria Donor Hearts for Transplantation: The OCS Heart EXPAND Trial
References 1. "Time is a precious commodity: 2018 OPTN policy change and the potential to lower heart transplant waitlist time in the sickest patients". Curr Cardiol Rep . 2019;21:7: 67. 2. "Does the heart transplant have a future?"Eur J Cardiothorac Surg . 2019;55:suppl 1: i38-i48. 3. "Epidemiology of heart failure". Circ Res . 2013;113:6: 646-659. 4. "The war against heart failure: the Lancet lecture". Lancet . 2015;385:9970: 812-824. 5. "Dilemmas in end-stage heart failure". J Geriatr Cardiol .
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure:
References 1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:993-1004. 2. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620. 3. "Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event". J Card Fail . 2023;29:922-930. 4.
Outcomes similar with heart donation after circulatory death vs. brain death
Source/Disclosures Disclosures: DeVore reports receiving advisory board, consultant, speaking and/or travel fees from Abbott Vascular, Abiomed, American Regent, Amgen, AstraZeneca, Biofourmis, Bodyport, Cardionomic, CareDx, Cytokinetics, InnaMed, LivaNova USA, Medscape, Novartis, Novo Nordisk, Procyrion, Story Health, Vifor and Zoll Services. Please see the study for all other authors’ relevant financial disclosures.
Transplantation Outcomes with Donor Hearts after Circulatory Death
Abstract Background Data showing the efficacy and safety of the transplantation of hearts obtained from donors after circulatory death as compared with hearts obtained from donors after brain death are limited.
A 'Game Changer' for Heart Transplant?
Recorded March 4, 2023. This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hello. This is Ileana Piña. I'm at Thomas Jefferson University, and this is my blog. I am thrilled today to have one of my good friends here with me, Dr Adam DeVore, who's the director of transplant at Duke University. There's been conversation about heart donations, and as most of you know, the hearts are not sitting on the shelf.
Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction
Oktay A.A. Rich J.D. Shah S.J. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013; 10: 401-410 Steinberg B.A. Zhao X. Heidenreich P.A. et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012; 126: 65-75 Virani S.S. Alonso A. Aparicio H.J. et al. Heart disease and Stroke Statistics—2021 update: a report from the American Heart Association. Circulation.
A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction-Reply | JAMA | JAMA Network
Comment & Response November 16, 2021 JAMA. 2021;326(19):1977-1978. doi:10.1001/jama.2021.16756 Original Investigation Effect of a Quality Improvement Intervention on Outcomes and Care Quality for Patients With HFrEF Adam D. DeVore, MD, MHS; Bradi B. Granger, PhD, RN; Gregg C. Fonarow, MD; Hussein R. Al-Khalidi, PhD; Nancy M. Albert, PhD; Eldrin F. Lewis, MD, MPH; Javed Butler, MD, MPH, MBA; Ileana L. Piña, MD, MPH; Larry A. Allen, MD, MHS; Clyde W. Yancy, MD; Lauren B. Cooper, MD, MHS; G.
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction
ABSTRACT Background Clinical practice guidelines support sustained use of renin-angiotensin-aldosterone-system (RAAS) inhibitors over time in heart failure with reduced ejection fraction, yet few data are available regarding the frequency, timing or predictors of early treatment discontinuation in clinical practice.
Can We Prevent Infections in Patients with Left Ventricular Assist Devices?
Editorial Comment Karen Flores Rosario MD, Department of Medicine, Division of Cardiology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States Dr. Flores Rosario reports no relevant disclosures. Search for more papers by this author Adam D.
Hospital, post-discharge quality improvement intervention failed to improve HFrEF outcomes
May 17, 2021 2 min read Save Source/Disclosures Published by: Source: Devore A, et al. Late Breaking Clinical Trials IV. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting). Disclosures: CONNECT-HF was funded by Novartis through an investigator-initiated trial program. DeVore reports he received research funding through his institution and provided consulting services for Novartis.
Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial | Cardiology | JAMA | JAMA Network
Key Points Question Can a hospital and postdischarge intervention focused on education on heart failure care as well as audit and feedback on care processes improve postdischarge outcomes and quality of care for patients with heart failure with reduced ejection fraction?
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients:
Abstract Objectives The authors sought to evaluate the association of heart failure hospitalization (HFH) with guideline-directed medical therapy (GDMT) prescribing patterns among patients with heart failure with reduced ejection fraction (HFrEF). Background HFH represents an important opportunity to titrate GDMT among patients with HFrEF. Methods The CHAMP-HF (Change the Management of Patients With Heart Failure) registry is a prospective registry of adults with HFrEF (ejection fraction ≤40%).
Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?
Abstract Heart failure (HF) is associated with significant morbidity and mortality. Although initially thought to be harmful in HF, beta-adrenergic blockers (β-blockers) have consistently been shown to reduce mortality and HF hospitalization in chronic HF with reduced ejection fraction. Proposed mechanisms include neurohormonal blockade and heart rate reduction.
Splanchnic Nerve Block for Chronic Heart Failure
JACC: Heart Failure Clinical Research Marat Fudim, Richard L. Boortz-Marx, Arun Ganesh, Adam D. DeVore, Chetan B. Patel, Joseph G. Rogers, Aubrie Coburn, Inneke Johnson, Amanda Paul, Brian J. Coyne, Sunil V. Rao, J. Antonio Gutierrez, Todd L. Kiefer, David F. Kong, Cynthia L. Green, W. Schuyler Jones, G. Michael Felker, Adrian F. Hernandez and Manesh R. Patel This article requires a subscription or purchase to view the full text.
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
Journal of the American College of Cardiology Original Investigation Andrew P. Ambrosy, Eugene Braunwald, David A. Morrow, Adam D. DeVore, Kevin McCague, Xiangyi Meng, Carol I. Duffy, Ricardo Rocha, Eric J. Velazquez and on behalf of the PIONEER-HF Investigators This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article. Author + information Andrew P.
CHAMP-HF: Certain factors confer improved LVEF in HFrEF
July 02, 2020 1 min read Save Source/Disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Splanchnic Nerve Block for Chronic Heart Failure
JACC: Heart Failure Clinical Research Marat Fudim, Richard L. Boortz-Marx, Arun Ganesh, Adam D. DeVore, Chetan B. Patel, Joseph G. Rogers, Aubrie Coburn, Inneke Johnson, Amanda Paul, Brian J. Coyne, Sunil V. Rao, J. Antonio Gutierrez, Todd L. Kiefer, David F. Kong, Cynthia L. Green, W. Schuyler Jones, G. Michael Felker, Adrian F. Hernandez and Manesh R. Patel This article requires a subscription or purchase to view the full text.
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF
JACC: Heart Failure Clinical Research Muthiah Vaduganathan, Gregg C. Fonarow, Stephen J. Greene, Adam D. DeVore, Abhishek Kavati, Slaven Sikirica, Nancy M. Albert, Carol I. Duffy, C. Larry Hill, J. Herbert Patterson, John A. Spertus, Laine E. Thomas, Fredonia B. Williams, Adrian F. Hernandez and Javed Butler This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article.
The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND‐HF
Research Article Robert J. Mentz Corresponding Author E-mail address: robert.mentz@duke.edu Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA Corresponding author. Duke Clinical Research Institute, PO Box 17 969, Durham, NC 27715, USA. Tel: +1 919 668‐7121, Fax: +1 919 668‐7063, Email: robert.mentz@duke.edu Search for more papers by this author Abstract Aims Non‐cardiac comorbidities are highly prevalent in patients with heart failure (HF).
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
Abstract Objectives This study sought to evaluate the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode) trial.
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure
Brief Report December 11, 2019 Key Points Question For patients recently hospitalized for acute decompensated heart failure (ADHF), what is the effect of administering sacubitril/valsartan?
PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Patients with HFpEF in GWTG-HF and a subset of patients meeting Broad-criteria and PARAGON-HF criteria. BNP, brain natriuretic peptide; eGFR, estimated glomerular ejection fraction, LVAD, left ventricular assist device; LVEF, left ventricular rejection fraction.
In‐hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time - Ambrosy - - European Journal of Heart Failure - Wiley Online Library
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Editorial Comment In‐hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time Andrew P.
Clinical profiles in acute heart failure: an urgent need for a new approach
Abstract Acute heart failure (HF) is a major public health concern, responsible for >26 million hospitalizations per year worldwide. Many trials have investigated new therapeutic options for acute HF, with most revealing equivocal results. Successful innovations in therapy for acute HF have remained limited, and standard of care has remained largely unchanged over the past decade, suggesting the need for a new approach for therapeutic decision making and clinical trial design in acute HF.
Heart Failure and Atrial Fibrillation, Like Fire and Fury
Heart failure and atrial fibrillation are 2 common cardiovascular disorders that frequently complicate one another and exert a significant detrimental effect on cardiovascular health and well-being. Both heart failure and atrial fibrillation continue to increase in prevalence as the risk factors underlying each condition become more common.
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article. Author + information vol. 73 no. 19 2365-2383 History: Received February 1, 2019 Revision received February 17, 2019 Accepted February 18, 2019 Published online May 13, 2019. Copyright & Usage: 2019 American College of Cardiology Foundation Stephen J. Greene, MDa,b@SJGreene_md, Gregg C.
Longitudinal Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article. Author + information Stephen J. Greene, MDa,b, Gregg C. Fonarow, MDc, Adam D. DeVore, MD, MHSa,b, Puza P. Sharma, MBBS, MPH, PhDd, Muthiah Vaduganathan, MD, MPHe, Nancy M. Albert, PhDf, Carol I. Duffy, DOd, C. Larry Hill, PhDa, Kevin McCague, MAd, J.Herbert Patterson, PharmDg, John A.
Heart Failure With Preserved Ejection Fraction and Diabetes
This work was supported by American Heart Association grant #16SFRN30180010 to Dr. Hernandez. The Get With The Guidelines–Heart Failure (GWTG-HF) program is provided by the American Heart Association. GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the American Heart Association Pharmaceutical Roundtable.
The impact of a failing right heart in patients supported by intra-aortic balloon counterpulsation
IABP-treated cardiogenic shock patients with biventricular failure more often required early escalation of mechanical circulatory support. However, there were no significant differences by type of ventricular failure with regard to 30-day outcomes. Among 107 patients, 60 patients (56%) had isolated left ventricular failure compared with 47 patients (44%) having biventricular failure.
Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? - Kelly - - European Journal of Heart Failure - Wiley Online Library
Corresponding Author E-mail address:jkelly@alaskaheart.com Alaska Heart & Vascular Institute, Anchorage, AK, USA Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA Corresponding author. 3841 Piper St. Suite T‐100, Anchorage, AK 99508, USA. Tel: +1 907 561‐3211, Fax: +1 907 264‐5744, Email: E-mail address:jkelly@alaskaheart.comSearch for more papers by this author
Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? - Kelly - 2018 - European Journal of Heart Failure - Wiley Online Library
Corresponding Author E-mail address:jkelly@alaskaheart.com Alaska Heart & Vascular Institute, Anchorage, AK, USA Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA Corresponding author. 3841 Piper St. Suite T‐100, Anchorage, AK 99508, USA. Tel: +1 907 561‐3211, Fax: +1 907 264‐5744, Email: E-mail address:jkelly@alaskaheart.comSearch for more papers by this author
Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes
Behavioral economics combines conventional economic principles with psychology to explain human behavior.
Improving heart failure health: is there a secret Swedish sauce?
Editorial CommentImproving heart failure health: is there a secret Swedish sauce?AuthorsAdam D. DeVore,Department of Medicine, Duke University School of Medicine, Durham, NC, USADuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USASearch for more papers by this authorAdrian F.
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
Patients enrolled in the RELAX trial of sildenafil in HFpEF (LV ejection fraction ?50%) in whom two-dimensional, speckle-tracking LV GLS was possible (n?=?187) were analysed. The distribution of LV GLS and its associations with clinical characteristics, LV structure and function, biomarkers, exercise capacity and quality of life were assessed. Baseline median LV GLS was ?14.6% (25th and 75th percentile, ?17.0% and ?11.9%, respectively) and abnormal (????16%) in 122/187 (65%) patients.
Can Vaccinations Improve Heart Failure Outcomes?
Heart failure (HF) affects approximately 5.7 million American adults, with a prevalence expected to increase over time (1–3). Despite marked pharmacologic and device-based advances for HF with reduced ejection fraction (EF) in recent years, HF is associated with significant morbidity, mortality, and financial burden. Approximately one-half of patients with chronic HF have preserved EF, with a prevalence expected to increase with aging of the population (4).
Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure
Introduction Readmission after a heart failure (HF) hospitalization is a common problem in the United States with >1 in 5 patients requiring rehospitalization within 30 days of discharge.1–4 HF readmissions are a burden to patients and come at an enormous expense to the healthcare system.4 Reducing hospital readmissions has become a national priority for healthcare providers, payers, and policy makers.
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry
Abstract Background: Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persist in contemporary outpatient practice is unclear. Objectives: This study sought to characterize patterns and factors associated with use and dose of HFrEF medications in current practice.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Adam D.
Contact Adam D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack